Effect of Two Different Doses of Neostigmine on the Gastric Residual Volume and Aspiration in Critically Ill Patients

NCT06687187 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2024-11-13

No results posted yet for this study

Summary

A study comparing the effect of two doses of neostigmine on the gastric residual volume in critically ill patients on enteral feeding.

Conditions

  • Gastric Reflux

Interventions

DRUG

Neostigmine

two groups (Group I, n= 41) and (Group II, n= 43) received varying doses of neostigmine (1 mg and 2 mg respectively

Sponsors & Collaborators

  • Zulekha Hospitals

    lead OTHER

Principal Investigators

  • abdalla e hassan, lecturer · lecturer

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-04-01
Completion
2024-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06687187 on ClinicalTrials.gov